Structure of RSL3
CAS No.: 1219810-16-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4), which reduces GPX4 expression and induces ferroptosis in head and neck cancer cells. In HN3 resistant cells, it increases the protein levels of p62 and Nrf2, leading to Keap1 inactivation.
Synonyms: (1S,3R)-RSL3
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Li, Donglin ; Li, Yingping ; Chen, Liangjie ; Gao, Chengchang ; Dai, Bolei ; Yu, Wenjia , et al.
Abstract: The natural product auraptene can influence tumor cell proliferation and invasion, but its effect on hepatocellular carcinoma (HCC) cells is unknown. Here, we report that auraptene can exert anti-tumor effects in HCC cells via inhibition of cell proliferation and ferroptosis induction. Auraptene treatment induces total ROS and lipid ROS production in HCC cells to initiate ferroptosis. The cell death or cell growth inhibition of HCC cells induced by auraptene can be eliminated by the ROS scavenger NAC or GSH and ferroptosis inhibitor ferrostatin-1 or Deferoxamine Mesylate (DFO). Mechanistically, the key ferroptosis defense protein SLC7A11 is targeted for ubiquitin–proteasomal degradation by auraptene, resulting in ferroptosis of HCC cells. Importantly, low doses of auraptene can sensitize HCC cells to ferroptosis induced by RSL3 and cystine deprivation. These findings demonstrate a critical mechanism by which auraptene exhibits anti-HCC effects via ferroptosis induction and provides a possible therapeutic strategy for HCC by using auraptene or in combination with other ferroptosis inducers.
Show More >
Keywords: auraptene ; HCC ; ferroptosis ; SLC7A11
Show More >
Yang, Haoying ; Dai, Bolei ; Chen, Liangjie ; Li, Yingping ; Jin, Xiaorui ; Gao, Chengchang , et al.
Abstract: Ferroptosis, a recently elucidated style of regulated cell death, has emerged as a significant area of investigation in cancer biology. Natural active compounds that have anti-cancer effects are promising candidates for cancer prevention. Iberverin, a natural compound derived from Brassica oleracea var. capitata, has been shown to exert anti-tumor activities in some cancers. However, its role in hepatocellular carcinoma (HCC) cells and the molecular mechanisms are still poorly understood. In this study, we proved that iberverin can induce intracellular reactive oxygen species (ROS) generation to inhibit cell proliferation and initiate ferroptotic cell death in HCC cells, which can be eradicated by the ferroptosis inhibitor ferrostatin-1 (Fer-1) or deferoxamine mesylate (DFO) and ROS scavenger (GSH or NAC). Mechanistically, iberverin treatment can simultaneously downregulate SLC7A11 mRNA level and degrade GPX4 through the ubiquitination pathway, leading to lipid peroxidation and ferroptotic cell death in HCC cells. Significantly, a low dose of iberverin can remarkably increase the sensitivity of HCC cells to ferroptosis induced by canonical ferroptosis inducers RSL3 and imidazole ketone erastin (IKE). This study uncovers a critical function of iberverin in preventing HCC through ferroptosis and provides a promising strategy for HCC treatment either via iberverin alone or in combination with canonical ferroptosis inducers in the future.
Show More >
Keywords: iberverin ; HCC ; ferroptosis ; GPX4 ; SLC7A11
Show More >
MDH2 Promotes Hepatocellular Carcinoma Growth through Ferroptosis Evasion via Stabilizing GPX4
Bian, Xueli ; Yu, Wenjia ; Li, Yingping ; Gao, Chengchang ; Dai, Bolei ; Yang, Haoying , et al.
Abstract: The crosstalk between tumor progression and ferroptosis is largely unknown. Here, we identify malate dehydrogenase 2 (MDH2) as a key regulator of ferroptosis. MDH2 deficiency inhibits hepatocellular carcinoma (HCC) cell growth and promotes sensitivity of HCC cells to RSL3-induced ferroptosis. MDH2 knockdown enhances RSL3-induced intracellular reactive oxygen species (ROS), free iron ions and lipid peroxides levels, leading to HCC ferroptotic cell death which is rescued by Ferrostatin-1 and iron chelator Deferiprone. Importantly, inhibition of HCC cell growth caused by MDH2 deficiency is partially rescued by ferroptosis blockade. Mechanistically, MDH2 resists RSL3-induced ferroptosis sensitivity by dependence on GPX4, which is stabilized by MDH2 in HCC. The protein expression of MDH2 and GPX4 is positively correlated with each other in HCC cell lines. Furthermore, The Cancer Genome Atlas (TCGA) database shows that MDH2 and GPX4 are highly expressed in HCC samples, their expression is positively correlated with HCC stages, and GPX4 expression is associated with poor prognosis of HCC patients. These findings reveal a critical mechanism by which HCC evades ferroptosis via MDH2-mediated stabilization of GPX4 to promote tumor progression and underscore the potential of MDH2 inhibition in combination with ferroptosis inducers for the treatment of HCC.
Show More >
Keywords: Tumor progression ; ferroptosis ; MDH2 ; HCC
Show More >
| CAS No. : | 1219810-16-8 |
| Formula : | C23H21ClN2O5 |
| M.W : | 440.88 |
| SMILES Code : | O=C([C@H]1CC2=C([C@H](C3=CC=C(C(OC)=O)C=C3)N1C(CCl)=O)NC4=C2C=CC=C4)OC |
| Synonyms : |
(1S,3R)-RSL3
|
| MDL No. : | MFCD30187526 |
| InChI Key : | TXJZRSRTYPUYRW-NQIIRXRSSA-N |
| Pubchem ID : | 1750826 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302-H315-H319-H335 |
| Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| HT22 mouse hippocampal neuronal cells | 80 nM | 24 hours | To evaluate the protective effect of catechol estrogens against erastin/RSL3-induced ferroptosis. Results showed that four catechol estrogens (2-OH-E1, 2-OH-E2, 4-OH-E1, and 4-OH-E2) significantly inhibited erastin/RSL3-induced cell death and reduced the accumulation of NO, ROS, and lipid-ROS. | Sci Rep. 2024 Oct 14;14(1):23988. |
| Pfa1 Gpx4-KO cells | 300 nM | 24 hours | To assess the sensitivity of FSP1 mutants to ferroptosis | Nat Struct Mol Biol. 2023 Nov;30(11):1806-1815. |
| Pfa1 cells | 500 nM | 2 days | To identify possible mutations affecting FSP1's ferroptosis-suppressive function | Nat Struct Mol Biol. 2023 Nov;30(11):1806-1815. |
| synovial fibroblasts | 0.125 μM | 12 hours | Evaluate the effect of RSL3 on ferroptosis in synovial fibroblasts, results showed RSL3 induced cell death and lipid peroxidation | Nat Commun. 2022 Feb 3;13(1):676 |
| C4-2 | 0.5 μM | 9 days | To evaluate the effect of RSL3 on prostate cancer cell colony formation, results showed that RSL3 significantly inhibited colony formation of prostate cancer cells. | Cancer Res. 2021 Mar 15;81(6):1583-1594. |
| PC3 | 0.125, 0.25, 0.5 μM | 72 h | To evaluate the effect of RSL3 on prostate cancer cell growth, results showed that all prostate cancer cell lines were sensitive to RSL3-induced ferroptosis. | Cancer Res. 2021 Mar 15;81(6):1583-1594. |
| DU145 | 0.125, 0.25, 0.5, 1, 2, and 4 μM | 72 h | To evaluate the effect of RSL3 on prostate cancer cell growth, results showed that all prostate cancer cell lines were sensitive to RSL3-induced ferroptosis. | Cancer Res. 2021 Mar 15;81(6):1583-1594. |
| G-361 | 0.5 µM | 24 h | RSL3 induced ferroptosis in G-361 cells, and overexpression of miR-137 suppressed RSL3-induced ferroptosis | Cell Death Differ. 2018 Aug;25(8):1457-1472. |
| A375 | 0.1 µM | 24 h | RSL3 induced ferroptosis in A375 cells, and overexpression of miR-137 suppressed RSL3-induced ferroptosis | Cell Death Differ. 2018 Aug;25(8):1457-1472. |
| HT29 cells | 3 µM | 24 h | RSL3 induced ferroptosis by increasing ROS levels and the cellular labile iron pool, leading to cell death. | Front Pharmacol. 2018 Nov 22;9:1371. |
| LoVo cells | 3 µM | 24 h | RSL3 induced ferroptosis by increasing ROS levels and the cellular labile iron pool, leading to cell death. | Front Pharmacol. 2018 Nov 22;9:1371. |
| HCT116 cells | 3 µM | 24 h | RSL3 induced ferroptosis by increasing ROS levels and the cellular labile iron pool, leading to cell death. | Front Pharmacol. 2018 Nov 22;9:1371. |
| PANC1 cells | 0.5 µM | 6 h | RSL3 induced cell death and lipid peroxidation in PANC1 cells, and CQ inhibited RSL3-induced cell death and lipid peroxidation. | Autophagy. 2021 Nov;17(11):3361-3374. |
| HT1080 cells | 0.5 µM | 6 h | RSL3 induced cell death and lipid peroxidation in HT1080 cells, and CQ inhibited RSL3-induced cell death and lipid peroxidation. | Autophagy. 2021 Nov;17(11):3361-3374. |
| 60 human cancer cell lines | 0.5 µM | 3 and 6 h | RSL3 exhibits wider and stronger activity in the upregulation of MAP1LC3B-II or downregulation of SQSTM1 in 80% (48/60) or 63% (38/60) of cell lines, respectively. Both RSL3 and erastin failed to affect SLC7A11 expression, but they led to GPX4 downregulation in 12% (7/60) and 3% (2/60) of cell lines, respectively. | Autophagy. 2021 Nov;17(11):3361-3374. |
| SH-SY5Y cells | 20 μM | To evaluate the inhibitory effect of RSL3 and erastin-induced ferroptosis in SH-SY5Y cells, it was found that ThA increased cell viability in a dose-dependent manner at concentrations of 2-16 μM. | Theranostics. 2024 Sep 23;14(16):6161-6184. | |
| PC-12 cells | 0.5 μM | 4, 8, 12, 24 h | To evaluate the inhibitory effect of RSL3-induced ferroptosis in PC-12 cells, it was found that ThA significantly increased cell survival and effectively prevented ferroptosis at all observed time points. | Theranostics. 2024 Sep 23;14(16):6161-6184. |
| Huh7 | 5 μM | RSL3 significantly suppressed the viability of Huh7 cells and induced ferroptosis. | Drug Des Devel Ther. 2021 Sep 18;15:3965-3978. | |
| HepG2 | 5 μM | RSL3 significantly suppressed the viability of HepG2 cells and induced ferroptosis. | Drug Des Devel Ther. 2021 Sep 18;15:3965-3978. | |
| human epidermal keratinocytes (HEKa) | 10 μM | 6 h | To assess the effect of RSL3 on cell viability, results showed that RSL3 treatment significantly reduced cell viability. | J Clin Invest. 2024 Nov 21;135(2):e183219. |
| EOC 20 microglial cells | 500 nM | 5 h | To test the sensitivity to RSL3-induced ferroptosis, M1-activated cells showed high resistance to RSL3, while M0 and M2-activated cells were susceptible. | Nat Chem Biol. 2020 Mar;16(3):278-290. |
| Bone marrow-derived macrophages (BMDM) | 500 nM | 5 h | To test the sensitivity to RSL3-induced ferroptosis, M1-activated cells showed high resistance to RSL3, while M0 and M2-activated cells were susceptible. | Nat Chem Biol. 2020 Mar;16(3):278-290. |
| RAW 264.7 macrophages | 500 nM | 5 h | To test the sensitivity to RSL3-induced ferroptosis, M1-activated cells showed high resistance to RSL3, while M0 and M2-activated cells were susceptible. | Nat Chem Biol. 2020 Mar;16(3):278-290. |
| HK2 cells | 1 μM | 24 h | RSL3 induces ferroptosis in HK2 cells, leading to increased lipid peroxidation and cell death. | Redox Biol. 2023 Dec;68:102939. |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| NSG (NOD-SCID-IL2R γ) male mice | Prostate cancer xenograft model | Intraperitoneal injection | 100 mg/kg | Twice per week, until the end of the experiment | To evaluate the effect of RSL3 on tumor growth in prostate cancer xenograft models, results showed that RSL3 significantly delayed tumor growth of DU145 and PC3 xenografts. | Cancer Res. 2021 Mar 15;81(6):1583-1594. |
| Nude mice | Subcutaneous tumor model | Intraperitoneal injection | 15 mg/kg | Twice every other day for 20 days | Knockdown of miR-137 enhanced erastin-induced ferroptosis and inhibited tumor growth | Cell Death Differ. 2018 Aug;25(8):1457-1472. |
| Mice | C57BL/6 mice | Topical application | 10 μM (120 μL) | Twice daily for 2 weeks | To evaluate the effect of RSL3 on mouse skin, results showed that RSL3 increased ferroptosis-specific oxPE species in the epidermis but did not induce psoriasis-like epidermal changes or immune cell infiltration. | J Clin Invest. 2024 Nov 21;135(2):e183219. |
| Mice | Zymosan-induced peritonitis model | Intraperitoneal injection | 40 mg/kg | Single injection, lasting 5 hours | To test the effect of RSL3 on M2 macrophages in vivo, RSL3 significantly reduced the number of M2 macrophages, while the NO donor DETA NONOate suppressed this reduction. | Nat Chem Biol. 2020 Mar;16(3):278-290. |
| Mice | AKI-CKD model | Intraperitoneal injection | 5 mg/kg | Daily for 14 days | RSL3 pretreatment significantly increased renal fibrosis and ferroptosis in AKI-CKD model mice and abrogated the anti-ferroptosis and renoprotective effects of RGFP966. | Redox Biol. 2023 Dec;68:102939. |
| Bio Calculators | ||||
| Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.27mL 0.45mL 0.23mL |
11.34mL 2.27mL 1.13mL |
22.68mL 4.54mL 2.27mL |
|
Tags: RSL3 | (1S |3R)-RSL3 | RSL 3 | RSL-3 | Glutathione Peroxidase | Ferroptosis | inhibit | RSL3 | (1S |3R)-RSL3 | glutathione peroxidase 4 | GPX4 | ferroptosis | regulated cell death | p62 | Nrf2 | Keap1 | HN3-rslR cells | oxidative stress | 1219810-16-8
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


